​

Estrella Immunopharma Stock (NASDAQ:ESLA)

FinancialsChart
Estrella Immunopharma by TradingView

Previous Close

$1.13

52W Range

$0.63 - $3.23

50D Avg

$0.98

200D Avg

$1.10

Market Cap

$43.78M

Avg Vol (3M)

$142.04K

Beta

0.24

Div Yield

-

ESLA Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Sep 14, 2021

Website

ESLA Performance

ESLA Financial Summary

Jun 24Dec 22Jun 22
Revenue---
Operating Income$-7.31M$-1.57M$-1.69M
Net Income$-7.31M$-996.10K$-1.69M
EBITDA$-7.31M$-1.57M$-1.69M
Basic EPS$-0.27$-0.17$-0.29
Diluted EPS$-0.27$-0.17$-0.29

Fiscal year ends in Jun 24 | Currency in USD